Hematologic Malignancy
Pediatric and/or Germline Mutation-Associated Myeloid Disorders
CI-CAN-00001395Explore in graph →
PediatricHematologicNon-malignant16 active trials1 approved drugs1 evidence items
- NCIt
- C198663
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001395Explore in graph →
Clinical trials
63 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | active not recruiting | Phase 3 | 280 | Children's Oncology GroupNETWORK | 6 | Aug 19, 2026 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER |
| 1 |
| Sep 28, 2023 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials